316 related articles for article (PubMed ID: 19879973)
1. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function.
Odunsi-Shiyanbade ST; Camilleri M; McKinzie S; Burton D; Carlson P; Busciglio IA; Lamsam J; Singh R; Zinsmeister AR
Clin Gastroenterol Hepatol; 2010 Feb; 8(2):159-65. PubMed ID: 19879973
[TBL] [Abstract][Full Text] [Related]
2. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis.
Rao AS; Wong BS; Camilleri M; Odunsi-Shiyanbade ST; McKinzie S; Ryks M; Burton D; Carlson P; Lamsam J; Singh R; Zinsmeister AR
Gastroenterology; 2010 Nov; 139(5):1549-58, 1558.e1. PubMed ID: 20691689
[TBL] [Abstract][Full Text] [Related]
3. Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome.
Camilleri M; Acosta A; Busciglio I; Boldingh A; Dyer RB; Zinsmeister AR; Lueke A; Gray A; Donato LJ
Aliment Pharmacol Ther; 2015 Mar; 41(5):438-48. PubMed ID: 25594801
[TBL] [Abstract][Full Text] [Related]
4. Effects of Colesevelam on Bowel Symptoms, Biomarkers, and Colonic Mucosal Gene Expression in Patients With Bile Acid Diarrhea in a Randomized Trial.
Vijayvargiya P; Camilleri M; Carlson P; Nair A; Nord SL; Ryks M; Rhoten D; Burton D; Busciglio I; Lueke A; Harmsen WS; Donato LJ
Clin Gastroenterol Hepatol; 2020 Dec; 18(13):2962-2970.e6. PubMed ID: 32088296
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of the effects of colesevelam on colonic transit in irritable bowel syndrome with diarrhea.
Wong BS; Camilleri M; Carlson PJ; Odunsi-Shiyanbade S; McKinzie S; Busciglio I; Burton D; Zinsmeister AR
Dig Dis Sci; 2012 May; 57(5):1222-6. PubMed ID: 22271411
[TBL] [Abstract][Full Text] [Related]
6. Bowel functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome.
Shin A; Camilleri M; Vijayvargiya P; Busciglio I; Burton D; Ryks M; Rhoten D; Lueke A; Saenger A; Girtman A; Zinsmeister AR
Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1270-1275.e1. PubMed ID: 23639599
[TBL] [Abstract][Full Text] [Related]
7. Relamorelin Relieves Constipation and Accelerates Colonic Transit in a Phase 2, Placebo-Controlled, Randomized Trial.
Acosta A; Camilleri M; Kolar G; Iturrino J; Szarka LA; Boldingh A; Burton D; Ryks M; Rhoten D; Zinsmeister AR; Spence SC; Gottesdiener K; Bouras EP; Vazquez-Roque MI
Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2312-9.e1. PubMed ID: 26001337
[TBL] [Abstract][Full Text] [Related]
8. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.
Andresen V; Camilleri M; Busciglio IA; Grudell A; Burton D; McKinzie S; Foxx-Orenstein A; Kurtz CB; Sharma V; Johnston JM; Currie MG; Zinsmeister AR
Gastroenterology; 2007 Sep; 133(3):761-8. PubMed ID: 17854590
[TBL] [Abstract][Full Text] [Related]
9. Colesevelam for the treatment of bile acid malabsorption-associated diarrhea in patients with Crohn's disease: a randomized, double-blind, placebo-controlled study.
Beigel F; Teich N; Howaldt S; Lammert F; Maul J; Breiteneicher S; Rust C; Göke B; Brand S; Ochsenkühn T
J Crohns Colitis; 2014 Nov; 8(11):1471-9. PubMed ID: 24953836
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial of 5-hydroxytryptamine4-receptor agonist, YKP10811, on colonic transit and bowel function in functional constipation.
Shin A; Acosta A; Camilleri M; Boldingh A; Burton D; Ryks M; Rhoten D; Zinsmeister AR
Clin Gastroenterol Hepatol; 2015 Apr; 13(4):701-8.e1. PubMed ID: 25148765
[TBL] [Abstract][Full Text] [Related]
11. Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome?
Sweetser S; Camilleri M; Linker Nord SJ; Burton DD; Castenada L; Croop R; Tong G; Dockens R; Zinsmeister AR
Am J Physiol Gastrointest Liver Physiol; 2009 Jun; 296(6):G1299-306. PubMed ID: 19342506
[TBL] [Abstract][Full Text] [Related]
12. Colonic Transit and Bile Acid Synthesis or Excretion in Patients With Irritable Bowel Syndrome-Diarrhea Without Bile Acid Malabsorption.
Peleman C; Camilleri M; Busciglio I; Burton D; Donato L; Zinsmeister AR
Clin Gastroenterol Hepatol; 2017 May; 15(5):720-727.e1. PubMed ID: 27856362
[TBL] [Abstract][Full Text] [Related]
13. Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation.
Wong BS; Camilleri M; McKinzie S; Burton D; Graffner H; Zinsmeister AR
Am J Gastroenterol; 2011 Dec; 106(12):2154-64. PubMed ID: 21876564
[TBL] [Abstract][Full Text] [Related]
14. Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome.
Camilleri M; Vazquez-Roque M; Iturrino J; Boldingh A; Burton D; McKinzie S; Wong BS; Rao AS; Kenny E; Månsson M; Zinsmeister AR
Am J Physiol Gastrointest Liver Physiol; 2012 Jul; 303(1):G120-8. PubMed ID: 22517769
[TBL] [Abstract][Full Text] [Related]
15. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial.
Kuiper EM; van Erpecum KJ; Beuers U; Hansen BE; Thio HB; de Man RA; Janssen HL; van Buuren HR
Hepatology; 2010 Oct; 52(4):1334-40. PubMed ID: 20683930
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of colesevelam for the treatment of bile acid diarrhoea: a double-blind, randomised, placebo-controlled, phase 4 clinical trial.
Borup C; Vinter-Jensen L; Jørgensen SPG; Wildt S; Graff J; Gregersen T; Zaremba A; Borup Andersen T; Nøjgaard C; Timm HB; Rainteau D; Hansen SH; Rumessen JJ; Munck LK
Lancet Gastroenterol Hepatol; 2023 Apr; 8(4):321-331. PubMed ID: 36758570
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and tolerability of colesevelam hydrochloride for bile-acid malabsorption in patients with cancer: a retrospective chart review and patient questionnaire.
Wedlake L; Thomas K; Lalji A; Anagnostopoulos C; Andreyev HJ
Clin Ther; 2009 Nov; 31(11):2549-58. PubMed ID: 20109999
[TBL] [Abstract][Full Text] [Related]
18. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects.
Davidson MH; Dillon MA; Gordon B; Jones P; Samuels J; Weiss S; Isaacsohn J; Toth P; Burke SK
Arch Intern Med; 1999 Sep; 159(16):1893-900. PubMed ID: 10493319
[TBL] [Abstract][Full Text] [Related]
19. Bile Acid Deficiency in a Subgroup of Patients With Irritable Bowel Syndrome With Constipation Based on Biomarkers in Serum and Fecal Samples.
Vijayvargiya P; Busciglio I; Burton D; Donato L; Lueke A; Camilleri M
Clin Gastroenterol Hepatol; 2018 Apr; 16(4):522-527. PubMed ID: 28666948
[TBL] [Abstract][Full Text] [Related]
20. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.
Harish K; Hazeena K; Thomas V; Kumar S; Jose T; Narayanan P
J Gastroenterol Hepatol; 2007 Aug; 22(8):1183-9. PubMed ID: 17688659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
